FDA Clearance Tracker · P920023-S010
UROLUME(R) ENDOPROSTHESIS
Last checked: Nov 20, 2026Latest source record: Feb 14, 2000 (this decision)Source: openFDAMethods & limitations
Decided
Feb 14, 2000
Approved
Time to decision
138 days
Received Sep 29, 1999. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P920023-S010
- Device name
- UROLUME(R) ENDOPROSTHESIS
- Applicant
- Boston Scientific Corp
- Applicant location
- Marlboro, MA
- Received
- Sep 29, 1999
- Decided
- Feb 14, 2000
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P920023
Device type
- Device class
- Class III
- Specialty
- GI, Urology & NephrologyUrology
FDA's approval statement
As written in FDA's record.
Extend the shelf life expiration dating up to 5 years.
Source documents
Other decisions for Boston Scientific Corp
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P130030 · Decided Mar 10, 2026 · 4,453 days after receipt
Device type: STENT, CORONARY (MAF) · Cardiology
- WATCHMAN FLX Left Atrial Appendage (LAA) Closure Technology, WATCHMAN FLX Left Atrial Appendage Closure Device with DeliPMA supplement
P130013-S074 · Decided Jul 16, 2025 · 180 days after receipt · Panel Track
Device type: System, appendage closure, left atrial (NGV) · Cardiology
K243245 · Decided Oct 18, 2024 · 7 days after receipt
Device type: Unit, Cryosurgical, Accessories (GEH) · General & Plastic Surgery
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.